Rtw Investments Adds $20M in Century Therapeutics, Inc. ($IPSC)

RTW Investments has made a significant move by taking a new position in Century Therapeutics, Inc. (NasdaqCM: IPSC). According to the latest Form 13F filing with the SEC, the fund acquired 8,695,652 shares, valued at approximately $19.6 million, as of May 15, 2026.

What Changed in RTW Investments' Century Therapeutics Position

RTW Investments' acquisition of 8,695,652 shares represents a new stake in Century Therapeutics, as the fund previously held no shares in the company. The value of this new position stands at roughly $19.6 million.

Other Institutional Activity in Century Therapeutics

Several other institutional investors have also shown interest in Century Therapeutics. Versant Venture Management, LLC added 24,332,218 shares, bringing its total to the same number, valued at around $54.9 million. TCG Crossover Management, LLC increased its holdings by 17,754,430 shares, ending with the same amount worth $39 million. RA Capital Management, L.P. also added 17,754,430 shares, totaling the same share count with a value of approximately $40.1 million. Deep Track Capital, LP grew its position by 9,487,745 shares, resulting in the same share count valued at about $21.4 million.

Century Therapeutics Stock Snapshot

Shares of Century Therapeutics (NasdaqCM: IPSC) were trading near $2.25. The company has a market capitalization of $405.8 million and shows a beta of 1.566, indicating higher volatility compared to the market. The stock's 52-week range is between $0.435 and $3.04, with a 50-day moving average of $2.28 and a 200-day moving average of $1.48. Century Therapeutics maintains a strong liquidity position with a current ratio of 10.25 and a quick ratio of 10.04, alongside a debt-to-equity ratio of 18.14.

Recent Earnings

Century Therapeutics reported a loss per share of $1.14. The company did not generate revenue growth, and it reported a negative return on equity of -42.67%. The net margin was also not available, reflecting the company's current focus on development rather than profitability. The next earnings date is set for May 13, 2026.

Insider Buying and Selling at Century Therapeutics, Inc.

Insider activity at Century Therapeutics has been notable. On June 11, 2026, insiders Lee Han Myung, Quimi Daphne, Blackwell Kimberly, Murphy Martin Patrick, and Riva Alessandro each purchased 74,000 shares. Additionally, Gregory Russotti, the Chief Technology and Manufacturing Officer, sold 524 shares on June 8, 2026, at an average price of $2.11.

Analysts Set New Price Targets

Analysts remain optimistic about Century Therapeutics. On May 27, 2026, Mizuho initiated coverage with a 'buy' rating and an $8.00 price target. HC Wainwright & Co. maintained a 'buy' rating with a $5.00 target as of April 21, 2026. Piper Sandler also upheld its 'buy' rating with a $4.00 target from January 20, 2026. Overall, the consensus among analysts is a 'buy' recommendation, with a mean price target of $4.75 from four analyst opinions.

About Century Therapeutics

Century Therapeutics, Inc. is a biotechnology company headquartered in Philadelphia, Pennsylvania. It focuses on developing allogeneic cell therapies to treat solid tumors, hematological malignancies, and autoimmune diseases. The company's lead product candidate, CNTY-813, is an iPSC-derived beta islet cell replacement therapy aimed at treating type 1 diabetes. Century Therapeutics is also working on CNTY-308 and CNTY-101, both of which target B-cell-mediated autoimmune diseases.

Bottom Line

RTW Investments' new stake in Century Therapeutics underscores the interest in the biotechnology firm's potential. Investors often track 13F filings like this to gauge institutional confidence, although these filings reflect past positions and may not indicate current holdings. Century Therapeutics' recent insider buying and positive analyst ratings suggest a company in a critical phase of development.